New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

Amir R. Dehdashti*, Monika E. Hegi, Luca Regli, Alessia Pica, Roger Stupp

*Corresponding author for this work

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

Standard care for newly diagnosed glioblastoma multiforme (GBM) previously consisted of resection to the greatest extent feasible, followed by radiotherapy. The role of chemotherapy was controversial and its efficacy was marginal at best. Five years ago temozolomide (TMZ) was approved specifically for the treatment of recurrent malignant glioma. The role of TMZ chemotherapy administered alone or as an adjuvant therapy for newly diagnosed GBM has been evaluated in a large randomized trial whose results suggested a significant prolongation of survival following treatment. Findings of correlative molecular studies have indicated that methylguanine methyltransferase promoter methylation may be used as a predictive factor in selecting patients most likely to benefit from such treatment. In this short review the authors summarize the current role of TMZ chemotherapy in the management of GBM, with an emphasis on approved indications and practical aspects.

Original languageEnglish (US)
Pages (from-to)E6
JournalNeurosurgical focus
Volume20
Issue number4
DOIs
StatePublished - 2006

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.'. Together they form a unique fingerprint.

  • Cite this